Editorial
|
|
|
|
|
Regulatory scrutiny should come first
|
|
|
|
New Products
|
|
|
|
|
A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties
|
|
|
|
|
|
|
|
|
|
|
|
In chronic HCV genotype 3 or 4 infection
|
|
|
|
|
|
|
|
|
|
|
|
Riskier than dinoprostone for inducing labour
|
|
|
|
Adverse Effects
|
|
|
|
|
Palpitations, rarely serious cardiac disorders
|
|
|
|
|
|
|
|
|
|
|
|
Suspected adverse reactions to new antivirals should be reported
|
|
|
|
|
|
|
|
|
|
Diagnostic agents can have serious adverse effects
|
|
|
|
|
|
|
|
|
|
This antihypertensive has an unfavourable harm-benefit balance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interim trial results favour levodopa in newly diagnosed disease
|
|
|
|
|
|
|
|
|
|
|
|
Publication journals fail to take violations into account
|
|
|
|
|
|